top of page

RETATRUTIDE

Retatrutide is a cutting-edge, triple-agonist peptide that targets GLP-1, GIP, and glucagon receptors, making it one of the most powerful metabolic therapies to date. It delivers unprecedented weight loss, surpassing even Semaglutide and Tirzepatide in clinical trials. Retatrutide enhances fat burning, reduces appetite, and improves insulin sensitivity while preserving lean muscle mass. It also supports cardiovascular health, inflammation reduction, and improved liver function. This multi-pathway approach makes Retatrutide uniquely effective for treating obesity, type 2 diabetes, and metabolic syndrome. With once-weekly dosing, it offers a transformative solution for long-term body composition and metabolic health optimization.

Benefits

Powerful Weight Loss Effects
​

  • Delivers greater weight loss than Semaglutide or Tirzepatide in trials

  • Promotes fat burning and energy expenditure via glucagon activity

  • Strong appetite suppression and increased satiety

  • Helps preserve lean muscle mass during weight loss

 
Metabolic Health
​

  • Improves insulin sensitivity and glucose control

  • May reduce risk or progression of type 2 diabetes

  • Enhances metabolic flexibility

 
Cardiovascular & Liver Support
​

  • Lowers blood pressure, cholesterol, and triglycerides

  • May improve non-alcoholic fatty liver disease (NAFLD)

  • Reduces systemic inflammation

 
Convenience & Comprehensive Results
​

  • Once-weekly injection for easy compliance

  • Multi-pathway action offers synergistic metabolic improvements

  • Potential support for long-term weight maintenance

Side Effects

Common Side Effects (typically dose-dependent and may lessen over time)
​

  • Nausea

  • Vomiting

  • Diarrhea

  • Constipation

  • Decreased appetite (may become excessive)

  • Stomach discomfort or bloating

  • Fatigue

  • Headache

 
Less Common / Moderate Side Effects
​

  • Dizziness or lightheadedness

  • Injection site reactions (redness, swelling, mild pain)

  • Increased heart rate (mild, due to glucagon activity)

  • Mild dehydration (due to GI issues or appetite loss)

 
Rare but Serious (Seek Medical Attention):
​

  • Pancreatitis (severe abdominal pain, persistent nausea)

  • Gallbladder issues (e.g., gallstones)

  • Thyroid C-cell tumors (seen in rodents; human risk unclear)

  • Kidney function changes (often secondary to dehydration)

 
Important Notes:
​

  • Most side effects improve with slow dose titration

  • Eating small, low-fat meals may help reduce GI discomfort

  • Clinical trials showed side effects similar to GLP-1 agonists but potentially more pronounced at higher doses

  • Always use under medical supervision

Dosages

Starting Dose:
​

  • 0.5 mg to 1.5 mg subcutaneously, once weekly

  • Purpose: To assess tolerance and minimize GI side effects

 
Titration Schedule (Example from Trials):
​

  • Increase by 1.5 mg every 4 weeks, as tolerated

  • Common dosing tiers:

    • Week 1–4: 1.5 mg

    • Week 5–8: 3.0 mg

    • Week 9–12: 4.5 mg

    • Week 13–16: 6.0 mg

    • Week 17+: 8.0 to 12.0 mg (max dose studied)

 
Administration:
​

  • Route: Subcutaneous injection

  • Frequency: Once weekly

  • Injection Sites: Abdomen, thigh, or upper arm

  • Storage: Keep refrigerated; use reconstituted solution promptly if not pre-filled

 
Important Notes:
​

  • Slow titration is essential to reduce nausea and GI side effects

  • Should be used only under clinical or professional medical supervision

  • Higher doses showed greater fat loss in trials but may increase side effects

​

Medical Disclaimer: These guidelines are for educational purposes only. Always consult a licensed medical professional before starting any peptide therapy.

  • Instagram
  • Twitter
© 2025 thepeptide.guide
bottom of page